WINTON GROUP Ltd Invests $2.37 Million in Alnylam Pharmaceuticals, Inc. $ALNY

WINTON GROUP Ltd acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, HoldingsChannel reports. The fund acquired 7,880 shares of the biopharmaceutical company’s stock, valued at approximately $2,372,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. iA Global Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 979.5% during the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares during the period. SCS Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $34,784,000. Hsbc Holdings PLC raised its position in shares of Alnylam Pharmaceuticals by 22.6% in the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after purchasing an additional 16,503 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $50,773,000. Finally, Keystone Investors PTE Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $3,531,000. 92.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ALNY shares. Stifel Nicolaus reduced their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Raymond James Financial upgraded Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a research report on Monday, August 3rd. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Royal Bank Of Canada reduced their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $376.67.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $248.68 on Friday. The stock has a market cap of $33.28 billion, a P/E ratio of 46.22 and a beta of 0.31. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The business’s 50-day moving average price is $254.43 and its two-hundred day moving average price is $288.99. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.Alnylam Pharmaceuticals’s revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).